PhRMA Sues To Block 'Unprecedented' California Price Reporting Law
Ban on WAC price increases violates Commerce Clause and reporting requirement violates First Amendment, PhRMA contends; complaint says state officials have not clarified whether law is retroactive.
You may also be interested in...
Under corporate integrity agreement, Mallinckrodt must post proposed list price increases for Acthar and other non-generic products along with a link to executive compensation. $234m settlement resolves allegations it underpaid Medicaid rebates resulting from Acthar price hikes.
PhRMA sues to block implementation of the law, saying it could allow states to compel manufacturers to dispense other medications without compensation.
Dozen drug pricing transparency bills enacted into law over past two years impose different requirements on manufacturers, with a few honing in on PBMs; interactive graphic details these and other pharma-related laws.